Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 9:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 12,657 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period A Clear all

Conditions: Neuromyelitis Optica Spectrum Disorder, NMOSD
Interventions: Satralizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Cardiovascular Diseases, Lung Diseases
Interventions: Minimal intervention, Enhanced Intervention; Behavioral
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 954 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Sleep Control Condition, Insomnia Symptoms Induction Condition
Interventions: Insomnia symptom induction; Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prophylaxis of Organ Rejection
Interventions: Mycophenolate Mofetil; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic, Arthritis, Juvenile, Adult Onset Still Disease
Interventions: Emapalumab; Drug
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 0 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: Dapagliflozin, Saxagliptin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 20
States / cities: Sacramento, California • New Haven, Connecticut • Hialeah, Florida + 12 more

Conditions: Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer
Interventions: Retifanlimab, Placebo, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, nab-Paclitaxel; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 583 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Anaheim, California • Whittier, California • Reading, Pennsylvania

Conditions: Cardiac Arrest, Pregnancy Related
Interventions: Electronic curriculum and instructor-led course, then placebo, Placebo, then electronic curriculum and instructor-led course; Other
Lead sponsor: UConn Health; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Cocaine Dependence, Opioid Dependence
Interventions: Disulfiram, Methadone, CBT, Lactose; Drug · Behavioral · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: End-Stage Renal Disease, Diabetes Mellitus
Interventions: IV Novolin R human insulin; Drug
Lead sponsor: State University of New York - Downstate Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Colorectal Cancer
Interventions: Capecitabine (Xeloda), Bevacizumab; Drug
Lead sponsor: Translational Oncology Research International; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 12
States / cities: Alhambra, California • Bakersfield, California • Fullerton, California + 9 more

Conditions: Heart Failure, Volume Overload
Interventions: Direct Sodium Removal Infusate 2.0; Drug
Lead sponsor: Sequana Medical N.V.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Noise Exposure, Noise-induced Hearing Loss, Noise; Adverse Effect, Mild Therapeutic Hypothermia, Cooling, Occupational Exposure, Occupational Health, Hidden Hearing Loss
Interventions: Cold pack-delivered mild therapeutic hypothermia; Device
Lead sponsor: Restorear Devices LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Endotracheal Extubation, Airway Obstruction, Airway Control, Pneumonia, Ventilator-Associated, Breathing Mechanics
Interventions: ETT cleaning maneuver; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 99 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Participants
Interventions: Brensocatib Oral Solution, Brensocatib Oral Tablet; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: COVID-19, SARS-CoV 2
Interventions: 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 245 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Psoriatic Arthritis
Interventions: Methotrexate, Anti-TNF; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Opioid Use Disorder, Posttraumatic Stress Disorder
Interventions: Prolonged exposure therapy, Financial incentives, Treatment as usual; Behavioral
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Dementia
Interventions: Tailored Activity Program, Attention Control; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Normal-Tension Glaucoma
Interventions: Sensimed Triggerfish, Blood Pressure; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy
Interventions: Green tea, 70% dark chocolate; Dietary Supplement
Lead sponsor: LifeBridge Health; Other
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Coal Workers' Pneumoconiosis (Complicated)
Interventions: Pirfenidone; Drug
Lead sponsor: Pulmonary Research of Abingdon, LLC; Other
Eligibility: 40 Years to 79 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Abingdon, Virginia

Conditions: Recurrent or Persistent Endometrial Carcinoma
Interventions: Sodium cridanimod; Drug
Lead sponsor: Kevelt AS; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 4
States / cities: San Jose, California • Santa Rosa, California • Detroit, Michigan + 1 more

Conditions: Metabolic Syndrome
Interventions: Professional nutrition counseling, No professional nutrition counseling; Other
Lead sponsor: Madigan Army Medical Center; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Tacoma, Washington

Search by objective public record fields.

A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Expanding the Role of Pharmacists in Treating Persons With Cardiovascular or Lung Diseases

Pain Sensitization and Habituation in a Model of Experimentally-induced Insomnia Symptoms

Bioequivalency Study of Mycophenolate Mofetil 250 mg Capsules Under Fasted Conditions

A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)

Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old

Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer

Obstetric Life Support, a Curriculum to Effectively Resuscitate Pregnant Patients Experiencing Cardiac Arrest.

Pharmacogenetics of Disulfiram for Cocaine

Pilot: Insulin Sensitivity/Management in Hyperglycemic Patients in Perioperative Period ESRD/Non-ESRD

Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer

Management of Volume Overload HF Patients by Individual DSR Treatment adJustment-a clinicAl inVestigation of InfusatE2.0

Non-Invasive System to Deliver Therapeutic Hypothermia for Protection Against Noise-Induced Hearing Loss

Efficacy Study of a Novel Device to Clean the Endotracheal Tube

A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants

SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding

National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study

Novel Telemedicine-Delivered Prolonged Exposure Therapy for Treating PTSD in Individuals With OUD

Tailored Activity Program-Veterans Affairs

Pilot Study on Ambulatory Intraocular Pressure and Blood Pressure Monitoring in Glaucoma

Flavonoid Effect on Activation and Stimulation of Thrombocytes, hsCRP and Lipid Profile

Examination of Pirfenidone (Esbriet®) Therapy in Coal Workers' Pneumoconiosis With Pulmonary Fibrosis

Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA

Precision Nutrition Impact on Health-Related Behavior Change